INTERIM SVR12 RESULTS FROM THE TELAPREVIR PHASE 3B REPLACE STUDY IN TREATMENT-NAIVE STABLE LIVER TRANSPLANT PATIENTS WITH GENOTYPE 1 HCV INFECTION

被引：0
|
作者：
Forns, X. [1 ,2 ]
Samuel, D. [3 ]
Mutimer, D. [4 ,5 ]
Fagiouli, S. [6 ]
Navasa, M. [7 ]
Agarwal, K. [8 ]
Berenguer, M. [9 ,10 ]
Colombo, M. [11 ]
Herzer, K. [12 ]
Nevens, F. [13 ]
Van Solingen-Ristea, R. [14 ]
Luo, D. [14 ]
Dierynck, I. [15 ]
Witek, J. [15 ]
机构：
[1] CIBEREHD, Liver Unit, Hosp Clin, Barcelona, Spain
[2] IDIBAPS, Barcelona, Spain
[3] Univ Paris South Villejuif, Hosp Paul Brousse, Ctr Hepatobiliaire, Paris, France
[4] Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England
[5] NIHR BRU, Birmingham, W Midlands, England
[6] Papa Giovanni XXIII Hosp, Gastroenterol & Transplant Hepatol, Bergamo, Italy
[7] Hosp Clin Barcelona, Liver Unit, Barcelona, Spain
[8] Kings Coll Hosp London, London, England
[9] Hosp La Fe, E-46009 Valencia, Spain
[10] CIBEREHD, Valencia, Spain
[11] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy
[12] Univ Hosp Essen, Liver Transplantat Unit, Essen, Germany
[13] Univ Hosp KU Leuven, Leuven, Belgium
[14] Janssen Res & Dev LLC, Titusville, NJ USA
[15] Janssen Infect Dis BVBA, Beerse, Belgium
来源：
JOURNAL OF HEPATOLOGY | 2014年 / 60卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1185
引用
收藏
页码：S481 / S481
页数：1
相关论文
共 50 条
  • [1] TREATMENT-NAIVE STABLE LIVER TRANSPLANT PATIENTS WITH GENOTYPE-1 HCV INFECTION: PHARMACOKINETIC RESULTS OF ADJUSTED DOSING WITH TACROLIMUS OR CYCLOSPORINE IN THE TELAPREVIR REPLACE STUDY
    Forns, X.
    Samuel, D.
    Mutimer, D.
    Fagiouli, S.
    Navasa, M.
    Agarwal, K.
    Berenguer, M.
    Colombo, M.
    Herzer, K.
    Nevens, F.
    Daems, B.
    Luo, D.
    Witek, J.
    Bertelsen, K.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S481 - S482
  • [2] VX-222/TELAPREVIR IN COMBINATION WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS TREATED FOR 12 WEEKS: ZENITH STUDY, SVR12 INTERIM ANALYSIS
    Nelson, David R.
    Gane, Edward J.
    Jacobson, Ira M.
    Di Bisceglie, Adrian M.
    Alves, Katia
    Koziel, Margaret J.
    De Souza, Cynthia
    Kieffer, Tara L.
    George, Shelley
    Rosario, Maria
    Kauffman, Robert S.
    Sulkowski, Mark S.
    HEPATOLOGY, 2011, 54 : 1435A - 1435A
  • [3] Telaprevir in Combination with Peginterferon and Ribavirin in Genotype 1 HCV Treatment-Naive Patients: Final Results of Phase 3 ADVANCE Study
    Ferenci, Peter
    Jacobson, Ira M.
    Adda, Nathalie
    Bengtsson, Leif
    George, Shelley
    Kauffman, Robert
    Zeuzem, Stefan
    SWISS MEDICAL WEEKLY, 2011, 141 : 3S - 3S
  • [4] TELAPREVIR IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN GENOTYPE 1 HCV TREATMENT-NAIVE PATIENTS: FINAL RESULTS OF PHASE 3 ADVANCE STUDY
    Jacobson, Ira M.
    McHutchison, John G.
    Dusheiko, Geoffrey M.
    Di Bisceglie, Adrian M.
    Reddy, Rajender
    Bzowej, Natalie H.
    Marcellin, Patrick
    Muir, Andrew J.
    Bengtsson, Leif
    Dunne, Ann Marie
    Adda, Nathalie
    George, Shelley
    Kauffman, Robert S.
    Zeuzem, Stefan
    HEPATOLOGY, 2010, 52 (04) : 427A - 427A
  • [5] TELAPREVIR IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN GENOTYPE 1 HCV TREATMENT-NAIVE PATIENTS: FINAL RESULTS OF PHASE 3 ADVANCE STUDY
    Dusheiko, G. M.
    Bengtsson, L.
    Adda, N.
    Kauffman, R.
    Jacobson, I. M.
    GUT, 2011, 60 : A32 - A33
  • [6] SVR12 results from the Phase II, open-label IMPACT study of simeprevir (SMV) in combination with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naive and -experienced patients with chronic HCV genotype 1/4 infection and decompensated liver disease
    Lawitz, Eric
    Poordad, Fred
    Gutierrez, Julio A.
    Kakuda, Thomas
    Picchio, Gaston
    Beets, Greet
    Vandevoorde, Ann
    Van Remoortere, Peter
    Jacquemyn, Bert
    Quinn, Gemma
    Luo, Donghan
    Ouwerkerk-Mahadevan, Sivi
    Vijgen, Leen
    Van Eygen, Veerle
    Beumont, Maria
    HEPATOLOGY, 2015, 62 : 227A - 227A
  • [7] 98% SVR12 IN KOREAN AND TAIWANESE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTION RECEIVING 12 WEEKS OF LEDIPASVIR/SOFOSBUVIR: RESULTS FROM AN INTERNATIONAL, MULTICENTER PHASE 3 STUDY
    Lim, Y. -S.
    Chuang, W. -L.
    Ahn, S. -H.
    Peng, C. -Y.
    Paik, S. -W.
    Chien, R. -N.
    Chu, C. -J.
    Yang, J. C.
    Mo, H.
    Gao, B.
    Pang, P. S.
    Knox, S. J.
    McHutchison, J. G.
    Lee, Y. -J.
    Chang, T. -T.
    Jeong, S. -H.
    Han, K. -H.
    Kao, J. -H.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S661 - S662
  • [8] SVR4 and SVR12 with an interferon-free regimen of BI201335 and BI207127, ± ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: interim results of SOUND-C2
    Zeuzem, Stefan
    Gane, Ed
    Roberts, Stuart
    Mensa, Federico
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 182 - 182
  • [9] SVR4 AND SVR12 WITH AN INTERFERON-FREE REGIMEN OF BI201335 AND BI207127, +/- RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION: INTERIM RESULTS OF SOUND-C2
    Zeuzem, S.
    Soriano, V.
    Asselah, T.
    Bronowicki, J. -P.
    Lohse, A.
    Muellhaupt, B.
    Schuchmann, M.
    Bourliere, M.
    Buti, M.
    Roberts, S.
    Gane, E.
    Stern, J. O.
    Kukolj, G.
    Dai, L.
    Boecher, W. O.
    Mensa, F. J.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S45 - S45
  • [10] Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study
    Lai Wei
    Qing Xie
    Jin Lin Hou
    Hong Tang
    Qin Ning
    Jun Cheng
    Yuemin Nan
    Lunli Zhang
    Jun Li
    Jianning Jiang
    Brian McNabb
    Fangqiu Zhang
    Gregory Camus
    Hongmei Mo
    Anu Osinusi
    Diana M. Brainard
    Guozhong Gong
    Zhuangbo Mou
    Shanming Wu
    Guiqiang Wang
    Peng Hu
    Yanhang Gao
    Jidong Jia
    Zhongping Duan
    Hepatology International, 2018, 12 : 126 - 132
12345